跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
楊 智宇
教授
臨床醫學研究所
https://orcid.org/0000-0001-9899-3159
電話
02-28767000 #66522
電子郵件
cyyang3
vghtpe.gov
tw
網站
https://icm.nycu.edu.tw/%e6%a5%8a%e6%99%ba%e5%ae%87-yang-chih-yu/
h-index
h10-index
h5-index
1798
引文
23
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1441
引文
20
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
643
引文
12
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2006
2024
每年研究成果
概覽
指紋
網路
研究成果
(109)
類似的個人檔案
(6)
指紋
查看啟用 Chih-Yu Yang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Acute Kidney Injury
32%
Adverse Cardiac Events
12%
All-cause Mortality
28%
Anemia
13%
Angiotensin Receptor Blockers
20%
Angiotensin-converting Enzyme Inhibitor (ACEi)
15%
Arteriovenous Fistula
53%
BK Virus Nephropathy
12%
Blood Flow Volume
12%
Chinese Patients
12%
Chronic Kidney Disease
41%
Chronic Kidney Disease Patients
26%
Clinical Outcomes
15%
Confidence Interval
38%
Dialysis
21%
Dialysis Patients
15%
End-stage Kidney Disease
14%
Erythropoiesis-stimulating Agents
15%
Far-infrared Therapy
12%
Functional Patency
12%
Hazard Ratio
30%
Hemodialysis
30%
Hemodialysis Patients
57%
Hospitalization
19%
Indoxyl Sulfate
13%
Kidney
14%
Long-term Hemodialysis
17%
Maintenance Hemodialysis Patients
58%
Mesenchymal Stem Cells
12%
Minimal Change Disease
12%
National Cohort Study
12%
Nautilus
12%
Nested Case-control Study
18%
Parathyroidectomy
12%
Patients with Hypertension
12%
Peritoneal Dialysis Patients
13%
Peritoneal Fibrosis
12%
Pneumocystis Jirovecii
14%
Prospective Observational Study
14%
Protein-to-creatinine Ratio
16%
Proteinuria
14%
Renal Function
21%
Renal Transplant Recipients
13%
Risk Factors
26%
Sepsis
23%
Serum Uric Acid
13%
Survivors
15%
Taiwan
23%
Type 2 Diabetic Patients
13%
Uremic Patients
16%
Medicine and Dentistry
ACE Inhibitor
18%
Acute Kidney Injury
29%
All Cause Mortality
10%
Analeptic
10%
Anemia
14%
Angiotensin Receptor Antagonist
18%
Arteriovenous Fistula
55%
Blood Flow
13%
Blood Vessel Calcification
13%
Bloodstream Infection
9%
Bone Development
12%
Cardiovascular System
14%
Chronic Kidney Disease
32%
Clinician
9%
Cohort Analysis
15%
Cohort Study
14%
Computer Assisted Tomography
10%
Continuous Erythropoiesis Receptor Activator
10%
Creatinine
15%
Dialysis Catheter
10%
Drug Dose Reduction
10%
End Stage Renal Disease
23%
Glomerular Filtration Rate
15%
Hazard Ratio
29%
Hematocrit
10%
Hemodialysis
100%
Hydronephrosis
10%
Immunosuppressant
22%
Infection
24%
Interleukin 6
10%
Iron
10%
Kidney Function
23%
Kidney Graft
21%
Kidney Transplantation
9%
Mortality Rate
9%
Nephropathy
12%
Parathyroid Hormone
9%
Parathyroidectomy
12%
Patient with Hypertension
12%
Peritoneal Dialysis
19%
Photoelectric Plethysmography
12%
Pneumocystis Pneumonia
12%
Proportional Hazards Model
14%
Renal Biopsy
12%
Renin Angiotensin Aldosterone System
13%
Respiratory Failure
11%
Sepsis
23%
Systemic Lupus Erythematosus
12%
Transplantation
9%
Vascular Access
15%
